Guangzhou Weiyuan (Vision Medicals) Gene Technology Co., Ltd. (hereinafter referred to as “Vision Medicals” or the “Company”), a leader in the infection precision medicine industry, recently announced the completion of a Series B financing round of several hundred million RMB. This round of financing was led by CDH Investment, with participation from CICC Qichen and existing shareholders, Volcanics Venture and Cash Capital. This round of financing will primarily be used for funding product R&D, establishing a clinical testing network, driving product registration efforts, constructing manufacturing facilities, improving clinical services, and increasing brand marketing.

CEC Capital Group served as the exclusive financial advisor of Vision Medicals in this transaction.

Vision Medicals focuses on innovation in genetic technologies and precision medicine focused on infectious diseases, and has two core technology platforms: pathogen metagenomics (mNGS) diagnosis and gene editing (CRISPR-Cas12/13) rapid diagnosis technology. Vision Medicals has established more than 5,000 square meters of medical testing laboratories, R&D centers, in-vitro diagnostic equipment, and reagent production GMP facilities in Beijing, Nanjing, Shanghai, Guangzhou and other locations in China.

Vision Medicals has established in-depth partnerships with top institutions such as the Institute of Pathogens of the Chinese Academy of Medical Sciences, Huashan Hospital (affiliated with Fudan University), Guangzhou Respiratory Health Research Institute, Shanghai Children's Medical Center, PLA General Hospital, China-Japan Friendship Hospital, and Zhongshan Hospital (affiliated with Fudan University), among others.

The Company to date has published more than 10 high-scoring SCI articles, applied for more than 20 invention patents, and has obtained 5 approvals. Vision Medicals is oriented to clinical departments such as respiratory, ICU, infectious diseases, pediatrics, hematology, and neurology, and has been a long-time provider of infectious disease diagnosis systems based on genomics, imaging, and EMR.

During the Covid-19 pandemic, Vision Medicals used innovative pathogen metagenomics technologies to participate in the detection and sequencing of the earliest clinical samples from Wuhan (2019/12/24) and Shanghai (2020/1/20), and cooperated with the Chinese Academy of Medical Sciences to share the first batch of the Covid-19 genome data (one of the first four genome sequences) to the world.

Vision Medicals actively shares research results with the academic community, and has published 6 SCI papers related to Covid-19 (total impact factor near 40 points), and as one of only two companies, the Company assisted the China Academy of Medical Sciences to develop a national reference for Covid-19 nucleic acid detection reagents. Three of Vision Medicals Covid-19 test kits have obtained CE marks, including the first pathogen metagenomics-based test kit approved by the European Medicines Agency (EMA).